JDRF Canadian Clinical Trial Network (CCTN) FY18 Postdoctoral Fellowship in Clinical Translation in T1D Program - March 27, 2018

JDRF Canadian Clinical Trial Network (JDRF CCTN) is pleased to announce that Eli Lilly Canada Inc. has provided $120,000 in support of two CCTN Post-Doctoral Fellows for one year in the sum of $60,000 each.

Support for Small Business Innovation Research to Develop New Open and Closed-Loop Automated Technologies for Better Type 1 Diabetes Therapy and Monitoring (SBIR) - March 21, 2018

The goal of this Funding Opportunity Announcement (FOA) is to stimulate bioengineers, physiologists, bio-behavioral researchers, and designers in academic centers and small businesses to develop new approaches to create devices/components with enhanced accuracy and less patient burden that will represent real advancements regarding safety and effectiveness of glucose control technologies including open and closed loop hormone replacement systems.

Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes - March 21, 2018

This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of novel and supportive technologies for the improvement of cell replacement interventions using novel biomaterials and devices for type 1 diabetes (T1D) treatment. 

Catalyst Award in Diabetes, Endocrinology and Metabolic Diseases - February 2, 2018

Purpose: The Catalyst Award in Diabetes, Endocrinology and Metabolic Diseases (Catalyst-DEMD) is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and possibly transforming studies in DEMD topic areas.